The effect of crocin on MS

INTERVENTION: Control group: patients receiving placebotwice daily. Intervention 1: Intervention group: Patients receiving 30 mg of crocin twice daily. Intervention 2: Control group: patients receiving placebotwice daily. Intervention group: Patients receiving 30 mg of crocin twice daily. Placebo Treatment ‐ Drugs CONDITION: Multiple sclerosis (of): NOS brain stem cord disseminated generalized Multiple sclerosis. ; Multiple sclerosis (of): NOS brain stem cord disseminated generalized PRIMARY OUTCOME: DNA damage. Timepoint: first week and fourth week. Method of measurement: ELISA. IL‐17. Timepoint: first week and fourth week. Method of measurement: ELISA. Lipid peroxidation. Timepoint: first week and fourth week. Method of measurement: ELISA. Thiol groups. Timepoint: first week and fourth week. Method of measurement: Spectrophotometery. TNF‐a. Timepoint: first week and fourth week. Method of measurement: ELISA. Total antioxidant capacity. Timepoint: first week and fourth week. Method of measurement: spectrophotometery. INCLUSION CRITERIA: INCLUSION CRITERIA: Recently diagnosed relapsing‐remitting MS patients; Patients between 20‐40 years old exclusion criteria: Receiving immunomodulatory drugs such as interferons; Diabetes; Chronic disease like cardiac, liver or kidney disease; Smoking; Pregnancy and lactation; EDSS>4; Any rheumatologic disease or vasculitis; History of hypersensitivity to saffron